Search

Displaying results 2951 - 2960 of 10000 in total
  1. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.

  2. Drug

    Oxogluric acid

    go.drugbank.com/drugs/DB08845
    InvestigationalNutraceutical

    Oxogluric acid (α-Ketoglutarate) is not approved for any indication in the world but is an investigational drug in the United States. … Physiologically, oxogluric acid acts in the Krebs cycle as an intermediate, is involved in transamination reactions during the metabolism of amino acids, forms glutamic acid by combining with ammonia,

  3. Drug

    Acetophenazine

    go.drugbank.com/drugs/DB01063
    Approved

    Acetophenazine is an antipsychotic drug of moderate-potency. It is used in the treatment of disorganized and psychotic thinking.

  4. Drug

    Samarium (153Sm) lexidronam

    go.drugbank.com/drugs/DB05273
    Approved

    The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain.

  5. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016. … [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.

  6. Drug

    Rubidium Rb-82

    go.drugbank.com/drugs/DB09479
    ApprovedInvestigational

    It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected

  7. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory

  8. Drug

    Levocabastine

    go.drugbank.com/drugs/DB01106
    Approved

    Levocabastine was discovered at Janssen Pharmaceutica in 1979.

  9. Drug

    Aclidinium

    go.drugbank.com/drugs/DB08897
    Approved

    FDA approved on July 24, 2012. … Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD).

  10. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label].

    Salts: 1-palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)), sodium saltSynonyms: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol, 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol